Cardiomyopathy: an overview.
Cardiomyopathy is an anatomic and pathologic diagnosis associated with muscle or electrical dysfunction of the heart. Cardiomyopathies represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Cardiomyopathies may be primary (i.e., genetic, mixed, or acquired) or secondary (e.g., infiltrative, toxic, inflammatory). Major types include dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. Although cardiomyopathy is asymptomatic in the early stages, symptoms are the same as those characteristically seen in any type of heart failure and may include shortness of breath, fatigue, cough, orthopnea, paroxysmal nocturnal dyspnea, and edema. Diagnostic studies include B-type natriuretic peptide levels, baseline serum chemistries, electrocardiography, and echocardiography. Treatment is targeted at relieving the symptoms of heart failure and reducing rates of heart failure-related hospitalization and mortality. Treatment options include pharmacotherapy, implantable cardioverter-defibrillators, cardiac resynchronization therapy, and heart transplantation. Recommended lifestyle changes include restricting alcohol consumption, losing weight, exercising, quitting smoking, and eating a low-sodium diet.
The Ohio State University, 456 W. 10th Ave., Columbus, OH 43210, USA. randy.wexler@osumc.edu
Randell K
RK
Wexler
Terry
T
Elton
Adam
A
Pleister
David
D
Feldman
D000465:Algorithms; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood; D040242:Risk Reduction Behavior
D000959:Antihypertensive Agents; D020097:Natriuretic Peptide, Brain